AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Summary

This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.

Timeline

Start

2008-06

Primary completion

2011-01

Completion

2011-05

Publications

• Fujisaka Y, Onozawa Y, Kurata T, Yasui H, Goto I, Yamazaki K, Machida N, Watanabe J, Shimada H, Shi X, Boku N. First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Invest New Drugs. 2013 Feb;31(1):108-14. doi: 10.1007/s10637-012-9809-7. Epub 2012 Mar 14.

Drugs

Indications